Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!

About | View Sample | Privacy

Hottest Products

Compare Top Solutions in:

Vaccine Production
Antibodies
Pharmaceutical Drug Development
Clinical Pharmacovigilance Studies
Bioavailability and Bioequivalence Studies
Toxicity Testing Laboratories

Evaluate more than 400,000 products >>

Featured Jobs

Director/Manager Supply and Distribution Operations
Seraphim Life Sciences LLC - Charleston, SC USA
Online Instructors - Master's Clinical Research Admnistration - Univ. of Liverpool
Laureate Online Education -
Opportunity Development Manager – New England/Eastern Canada
The Jackson Laboratory - Northern Massachusetts
Health Economics Consultant
Xcelerate Health Outcomes - London, UK
Manufacturing & Quality Operations positions
Genzyme -

More Jobs >>

Events

DIA 2011: Convergence of Science, Medicine, and Health
June 19-23, 2011 — Chicago, Illinois
Best Practices for the Prevention of Cargo and Warehouse Theft of FDA-Regulated Medical Products and Infant Formula
May 13, 2011 — Rockville, MD
Sensors Expo & Conference Conference
June 6-8, 2011 — Donald E. Stephens Convention Center Rosemont, IL
DIA 2011: Convergence of Science, Medicine, and Health
June 19-23, 2011 — Chicago, IL

More Events >>

Related Tags >> Merck HPV Gardasil

FDA rejection News

Most Popular FDA rejection Story

FDA rejects Merck's Gardasil for women over 26

April 7, 2011 — 9:54am ET | By Erica Teichert

The FDA has rejected Merck's ($MRK) request to market its HPV vaccine Gardasil to women between the ages of 27 and 45. The company had hoped the expanded use could boost slumping sales, which dropped Read more...

FDA rejection Press Releases

FDA Declines to Approve Santarus Inc. (SNTS)'s OTC Heartburn Drug
Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome
PRESS RELEASE: Indevus Receives Non-Approvable Letter From FDA for VALSTAR

Latest Headlines

FDA rejects Merck's Gardasil for women over 26
April 7, 2011

Paid Research Reports

Trends in mHealth and Telemedicine
The Global Aesthetic Dermatology Market Outlook
Future Directions in Regenerative Medicine
Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

More Research Reports >>

THE FIERCEMARKETS NETWORK